US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Noble hydrazonic history of anthracycline and methods for their preparation
|
KR0184860B1
(ko)
|
1988-11-11 |
1999-04-01 |
메디칼 리써어치 카운실 |
단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
|
JPH06507404A
(ja)
|
1991-05-01 |
1994-08-25 |
ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン |
感染性の呼吸性疾患の治療方法
|
ES2206447T3
(es)
|
1991-06-14 |
2004-05-16 |
Genentech, Inc. |
Anticuerpo humanizado para heregulina.
|
US5622929A
(en)
*
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
JP2000503639A
(ja)
|
1995-12-22 |
2000-03-28 |
ブリストル―マイヤーズ スクイブ カンパニー |
分枝ヒドラゾンのリンカー類
|
US5985320A
(en)
|
1996-03-04 |
1999-11-16 |
The Penn State Research Foundation |
Materials and methods for enhancing cellular internalization
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
PT954282E
(pt)
|
1997-01-16 |
2005-06-30 |
Massachusetts Inst Technology |
Preparacao de particulas para inalacao
|
CA2336139C
(fr)
|
1998-06-24 |
2008-10-14 |
Advanced Inhalation Research, Inc. |
Grandes particules poreuses emises par un inhalateur
|
US6019963A
(en)
|
1998-11-20 |
2000-02-01 |
D.S.C. Products, Inc. |
Deodorizing composition containing tea tree and eucalyptus oils
|
US7109019B2
(en)
|
1999-01-06 |
2006-09-19 |
The Regents Of The University Of California |
Gene cluster for production of the enediyne antitumor antibiotic C-1027
|
MXPA03010035A
(es)
|
2001-05-02 |
2004-06-30 |
Purdue Research Foundation |
Tratamiento y diagnostico de enfermedades mediadas por macrofagos.
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7297511B2
(en)
|
2001-10-10 |
2007-11-20 |
Neose Technologies, Inc. |
Interferon alpha: remodeling and glycoconjugation of interferon alpha
|
US7226903B2
(en)
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
US7265085B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7179617B2
(en)
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7399613B2
(en)
|
2001-10-10 |
2008-07-15 |
Neose Technologies, Inc. |
Sialic acid nucleotide sugars
|
US8008252B2
(en)
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7439043B2
(en)
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
EP1531846A4
(fr)
|
2002-02-27 |
2006-04-19 |
Us Gov Health & Human Serv |
Conjugues de ligand, adaptateur et agent cytotoxique, compositions associees et procedes d'utilisation relatifs
|
EP1545613B9
(fr)
*
|
2002-07-31 |
2012-01-25 |
Seattle Genetics, Inc. |
Conjugues d'auristatine et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
|
JP2004119755A
(ja)
|
2002-09-27 |
2004-04-15 |
Alps Electric Co Ltd |
磁気検出素子及びその製造方法
|
US20040071540A1
(en)
|
2002-10-15 |
2004-04-15 |
Lucas Philip J. |
Disposable/recyclable pallet system and method
|
US20080025989A1
(en)
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
BRPI0414568A
(pt)
|
2003-09-18 |
2006-11-07 |
Combinatorx Inc |
combinações de drogas para o tratamento de neoplasmas
|
US6997024B2
(en)
|
2003-10-01 |
2006-02-14 |
Truth Hardware Corporation |
Pull door lock
|
US8012944B2
(en)
|
2003-10-30 |
2011-09-06 |
Pharmascience Inc. |
Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
|
US20050148535A1
(en)
|
2003-10-30 |
2005-07-07 |
Lacasse Eric |
IAP nucleobase oligomers and oligomeric complexes and uses thereof
|
AU2005214331B2
(en)
|
2004-02-12 |
2011-09-15 |
Eisai, Inc. |
Monoclonal antibodies that specifically bind to folate receptor alpha
|
US7117807B2
(en)
|
2004-02-17 |
2006-10-10 |
University Of Florida Research Foundation, Inc. |
Dynamically modifiable polymer coatings and devices
|
WO2006073419A2
(fr)
|
2004-04-01 |
2006-07-13 |
Gang Zheng |
Nanoplateformes lipoproteiniques
|
JP2007537164A
(ja)
|
2004-05-07 |
2007-12-20 |
マサチューセッツ・インスティテュート・オブ・テクノロジー |
リン酸化bach1のbrca1brctドメイン認識と関係する癌治療のための方法および組成物
|
EP2522663B1
(fr)
|
2004-06-03 |
2015-04-01 |
Eisai R&D Management Co., Ltd. |
Intermédiaires pour la préparation d'halichondrine b
|
EP1791565B1
(fr)
|
2004-09-23 |
2016-04-20 |
Genentech, Inc. |
Anticorps et conjugues produits avec de la cysteine
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
JP2008522624A
(ja)
|
2004-12-09 |
2008-07-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ヘミアスタリン(hemiasterlin)アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
|
WO2006076100A2
(fr)
|
2004-12-09 |
2006-07-20 |
Eisai Co. Ltd. |
Criblage de l'isotype tubuline en therapie du cancer faisant appel aux analogues de l'halichondrine b
|
WO2007008848A2
(fr)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Composes de monomethylvaline presentant des modifications carboxy phenylalanine a la terminaison c
|
CA2614436C
(fr)
|
2005-07-07 |
2016-05-17 |
Seattle Genetics, Inc. |
Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
|
GB0515025D0
(en)
|
2005-07-21 |
2005-08-31 |
Novartis Ag |
Organic compounds
|
KR20130113543A
(ko)
|
2005-08-19 |
2013-10-15 |
엔도사이트, 인코포레이티드 |
복수-약제 리간드 공액체
|
CA2620362A1
(fr)
|
2005-09-14 |
2007-03-22 |
Ucb Pharma S.A. |
Polymeres a structure en peigne
|
CA2632903C
(fr)
|
2005-12-02 |
2015-11-24 |
Vianova Labs, Inc. |
Traitement du cancer et d'autres maladies
|
EP2021502A4
(fr)
|
2006-05-09 |
2010-08-25 |
Mas Metabolic Analytical Servi |
Gènes et marqueurs atypiques dans le diabète de type 2 et l'obésité
|
US20150030534A1
(en)
|
2013-07-26 |
2015-01-29 |
Rutgers, The State University Of New Jersey |
Antibody cocktails for breast cancer radioimmunotherapy
|
US20140037539A1
(en)
|
2012-07-27 |
2014-02-06 |
Rutgers, The State University Of New Jersey |
Antibody cocktails for breast cancer radioimmunotherapy
|
US8398956B2
(en)
|
2007-01-11 |
2013-03-19 |
Immunomedics, Inc. |
In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
|
WO2008101231A2
(fr)
|
2007-02-16 |
2008-08-21 |
Endocyte, Inc. |
Procédés et compositions de traitement et de diagnostic d'une maladie rénale
|
EP2481427A1
(fr)
|
2007-03-14 |
2012-08-01 |
Endocyte, Inc. |
Conjugués de folate et de tubulysine
|
EP1977765A1
(fr)
|
2007-04-03 |
2008-10-08 |
Diatos |
Promédicaments de peptide
|
US8093410B2
(en)
|
2007-10-03 |
2012-01-10 |
Eisai R&D Management Co., Ltd. |
Intermediates and methods for the synthesis of halichondrin B analogs
|
JP5065228B2
(ja)
|
2007-10-30 |
2012-10-31 |
富士通株式会社 |
携帯端末装置
|
NO2842575T3
(fr)
|
2008-03-18 |
2018-02-24 |
|
|
WO2009121031A1
(fr)
|
2008-03-27 |
2009-10-01 |
Vascular Biosciences, Inc. |
Procédé d'identification de nouveaux candidats thérapeutiques via l'analyse d'expression génique dans les maladies d'origine vasculaire
|
US20100260668A1
(en)
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
SG189817A1
(en)
*
|
2008-04-30 |
2013-05-31 |
Immunogen Inc |
Potent conjugates and hydrophilic linkers
|
CA2726087A1
(fr)
|
2008-06-03 |
2009-12-10 |
Tariq Ghayur |
Immunoglobulines a deux domaines variables et leurs utilisations
|
RU2010153578A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойными вариабельными доменами и их применение
|
RU2011104348A
(ru)
|
2008-07-08 |
2012-08-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
|
JP2010090117A
(ja)
|
2008-09-12 |
2010-04-22 |
Santen Pharmaceut Co Ltd |
スルホン酸エステル構造を導入したフェニル基を置換基として有する新規1,2,3,4−テトラヒドロキノキサリン誘導体からなるグルココルチコイド受容体アゴニスト
|
BRPI0922807A2
(pt)
|
2008-12-04 |
2015-12-22 |
Abbott Lab |
imonuglobulinas de domínio variável duplo e usos dos mesmos
|
EP2810652A3
(fr)
|
2009-03-05 |
2015-03-11 |
AbbVie Inc. |
Protéines se liant à un IL-17
|
US20140339088A1
(en)
|
2009-03-09 |
2014-11-20 |
Virginia Tech Intellectual Properties, Inc. |
Dielectrophoresis methods for determining a property of a plurality of cancer cells
|
RU2011148913A
(ru)
|
2009-05-01 |
2013-06-10 |
Эбботт Лэборетриз |
Иммуноглобулин с двумя вариабельными доменами и его применение
|
US8686520B2
(en)
*
|
2009-05-29 |
2014-04-01 |
International Business Machines Corporation |
Spin-torque magnetoresistive structures
|
UY32808A
(es)
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
WO2011022264A1
(fr)
*
|
2009-08-15 |
2011-02-24 |
Genentech, Inc. |
Thérapie anti-angiogenèse pour le traitement dun cancer du sein précédemment traité
|
KR20120060877A
(ko)
|
2009-09-01 |
2012-06-12 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
GB0917044D0
(en)
|
2009-09-29 |
2009-11-18 |
Cytoguide As |
Agents, uses and methods
|
AU2010306677B2
(en)
|
2009-10-15 |
2013-05-23 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
NZ599866A
(en)
|
2009-11-06 |
2014-09-26 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
CN102803254B
(zh)
|
2010-01-26 |
2016-09-14 |
卫材R&D管理有限公司 |
用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物
|
CA2794266C
(fr)
|
2010-03-24 |
2020-09-08 |
Ohio University |
Compositions et procedes pour l'inhibition du transport du glucose
|
US8710035B2
(en)
|
2010-03-24 |
2014-04-29 |
The University Of Chicago |
Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
|
SI2571532T1
(sl)
|
2010-05-14 |
2017-10-30 |
Abbvie Inc. |
Proteini, ki vežejo IL-1
|
JP6055404B2
(ja)
|
2010-06-15 |
2016-12-27 |
ゲンマブ エー/エス |
組織因子に対するヒト抗体薬物結合体
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
CA2809433A1
(fr)
|
2010-08-26 |
2012-03-01 |
Abbvie Inc. |
Immunoglobulines a deux domaines variables et leurs utilisations
|
US9089570B2
(en)
|
2010-09-03 |
2015-07-28 |
Tactical Therapeutics Inc |
Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
|
US9192677B2
(en)
|
2010-09-07 |
2015-11-24 |
Johannes Kepler Universität Linz |
Biodegradable, water soluble and pH responsive poly(organo)phosphazenes
|
WO2012065057A2
(fr)
|
2010-11-12 |
2012-05-18 |
Exelixis, Inc. |
Inhibiteurs de la phosphatidylinositol 3-kinase et leurs procédés d'utilisation
|
WO2012065019A2
(fr)
|
2010-11-12 |
2012-05-18 |
Exelixis, Inc. |
Inhibiteurs pyridopyrimidinone de p13k alpha
|
WO2012075361A2
(fr)
|
2010-12-02 |
2012-06-07 |
Immunomedics, Inc. |
Chimie click exempte de cuivre in vivo pour l'administration d'agents thérapeutiques et/ou diagnostiques
|
KR20130133247A
(ko)
|
2010-12-21 |
2013-12-06 |
애브비 인코포레이티드 |
Il-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
|
UY33826A
(es)
|
2010-12-22 |
2012-07-31 |
Abbott Lab |
Proteínas de unión con dominios trivariables y sus usos
|
UY33827A
(es)
|
2010-12-22 |
2012-07-31 |
Abbott Lab |
Proteínas de unión a media-inmunoglobulina y sus usos
|
EP2675474B1
(fr)
|
2011-02-15 |
2019-01-16 |
Vaxiion Therapeutics, LLC |
Compositions thérapeutiques et procédés d'administration ciblée de molécules bioactives par des minicellules bactériennes basée sur des molécules de ciblage contenant un fragment fc et des anticorps
|
WO2012116277A1
(fr)
|
2011-02-25 |
2012-08-30 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur cannabinoïde
|
EP2680839A1
(fr)
|
2011-03-02 |
2014-01-08 |
Morphotek, Inc. |
Co-administration d'éribuline et de farletuzumab pour le traitement du cancer du sein
|
WO2012118978A1
(fr)
|
2011-03-03 |
2012-09-07 |
The Regents Of The University Of Colorado, A Body Corporate |
Procédés pour traiter des cancers positifs aux oncovirus
|
WO2012121973A1
(fr)
|
2011-03-04 |
2012-09-13 |
Life Technologies Corporation |
Composés et procédés de conjugaison de biomolécules
|
JP5971769B2
(ja)
|
2011-03-15 |
2016-08-17 |
ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル |
アントラサイクリン療法を用いて乳癌を処置する方法
|
EP2686441B1
(fr)
|
2011-03-18 |
2019-05-08 |
Eisai R&D Management Co., Ltd. |
Procédé et utilisation pour prédire la réponse à l'éribuline
|
EP2670866A4
(fr)
|
2011-04-05 |
2015-09-02 |
Translational Genomics Res Inst |
Biomarqueurs et leurs procédés d'utilisation
|
EP2508525A1
(fr)
|
2011-04-05 |
2012-10-10 |
Bayer Pharma Aktiengesellschaft |
Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
|
US9132131B2
(en)
|
2011-04-21 |
2015-09-15 |
Saint Louis University |
Use of adenosine A3 receptor agonists for treatment of neuropathic pain
|
MX371526B
(es)
|
2011-05-27 |
2020-01-31 |
Ambrx Inc |
Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
|
MX359217B
(es)
|
2011-05-27 |
2018-09-19 |
Ambrx Inc |
Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales.
|
WO2012170640A1
(fr)
|
2011-06-07 |
2012-12-13 |
The Trustees Of Columbia University In The City Of New York |
Procédés et compositions pour traitement par une combinaison trail-médicament
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
ES2622578T3
(es)
|
2011-06-10 |
2017-07-06 |
Mersana Therapeutics, Inc. |
Conjugados de proteína-polímero-fármaco
|
EP3321281B1
(fr)
|
2011-08-05 |
2019-11-27 |
biOasis Technologies Inc |
Fragments de p97 avec activité de transfert
|
WO2013078559A1
(fr)
|
2011-11-30 |
2013-06-06 |
Alphora Research Inc. |
Procédé de préparation de (3r)-2,4-di-groupe partant-3-méthylbut-1-ène
|
CN104024237B
(zh)
|
2011-12-16 |
2016-02-24 |
阿方拉研究股份有限公司 |
用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
WO2013092983A2
(fr)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Conjugaison enzymatique de polypeptides
|
CA2860446C
(fr)
|
2011-12-29 |
2017-01-10 |
Alphora Research Inc. |
Derives de 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofurane-2-yl)acetaldehyde et procede pour leur preparation
|
AR092790A1
(es)
|
2012-02-01 |
2015-05-06 |
Euro Celtique Sa |
Derivados bencimidazolicos del acido hidroxamico
|
WO2013130093A1
(fr)
*
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
|
WO2013138371A1
(fr)
|
2012-03-12 |
2013-09-19 |
Merrimack Pharmaceuticals, Inc. |
Procédés de traitement du cancer du pancréas à l'aide de thérapies combinées comprenant un anticorps anti-erbb3
|
US9358235B2
(en)
|
2012-03-19 |
2016-06-07 |
Plexxikon Inc. |
Kinase modulation, and indications therefor
|
EP2830648A4
(fr)
|
2012-03-29 |
2015-12-02 |
Altor Bioscience Corp |
Procédés de traitement de la néoplasie
|
EP2831082B1
(fr)
|
2012-03-30 |
2019-02-20 |
Sandoz AG |
Procédé de synthèse pour la préparation d'analogues c1-céto macrocycliques de l'halichondrine b et intermédiaires utiles dans celui-ci
|
CN104684579A
(zh)
|
2012-04-02 |
2015-06-03 |
梅里麦克制药股份有限公司 |
单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
|
US9981046B2
(en)
|
2012-05-15 |
2018-05-29 |
Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. |
Drug-conjugates, conjugation methods, and uses thereof
|
BR112014028396A2
(pt)
|
2012-05-15 |
2018-05-29 |
Diatech Oncology |
processo de isolamento/purificação de célula de tumor e métodos para uso da mesma
|
SG11201408153YA
(en)
|
2012-06-07 |
2015-01-29 |
Ambrx Inc |
Prostate-specific membrane antigen antibody drug conjugates
|
MX2014014831A
(es)
|
2012-06-08 |
2015-02-12 |
Hoffmann La Roche |
Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
|
AU2013277169B2
(en)
|
2012-06-19 |
2017-02-02 |
Ambrx, Inc. |
Anti-CD70 antibody drug conjugates
|
CA2877378A1
(fr)
|
2012-06-29 |
2014-01-03 |
Nanostring Technologies, Inc. |
Methodes de traitement du cancer du sein par une therapie par la gemcitabine
|
US9220695B2
(en)
|
2012-06-29 |
2015-12-29 |
The Research Foundation For The State University Of New York |
Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances
|
CA2878733C
(fr)
|
2012-07-12 |
2021-09-14 |
Hangzhou Dac Biotech Co., Ltd |
Conjugues de molecule de liaison cellulaire et d'agents cytotoxiques
|
US20140069822A1
(en)
|
2012-09-10 |
2014-03-13 |
Antec Leyden B.V. |
Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
|
US9872919B2
(en)
|
2012-09-19 |
2018-01-23 |
The Research Foundation For The State University Of New York |
Prodrugs for selective anticancer therapy
|
AU2013326463B2
(en)
|
2012-10-04 |
2018-01-18 |
Ab Science |
Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
|
US20150275306A1
(en)
|
2012-10-10 |
2015-10-01 |
Stichting Het Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis |
Methods and means for predicting resistance to anti-cancer treatment
|
WO2014063443A1
(fr)
|
2012-10-22 |
2014-05-01 |
Zhang Yuliang |
Procédé de travail thermique auto-refroidissant
|
JP6855661B2
(ja)
|
2012-10-23 |
2021-04-07 |
シンアフィックス ビー.ブイ. |
修飾抗体、抗体コンジュゲート及びそれらを調製する方法
|
PT2917195T
(pt)
|
2012-11-05 |
2018-02-09 |
Pfizer |
Análogos de spliceostatina
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
CN105283182A
(zh)
|
2012-12-03 |
2016-01-27 |
卡利泰拉生物科技公司 |
用谷氨酰胺酶的杂环抑制剂治疗癌症
|
TW201425336A
(zh)
*
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
US9243058B2
(en)
|
2012-12-07 |
2016-01-26 |
Amgen, Inc. |
BCMA antigen binding proteins
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
JP6334553B2
(ja)
|
2012-12-10 |
2018-05-30 |
メルサナ セラピューティクス,インコーポレイティド |
タンパク質−高分子−薬剤コンジュゲート
|
US9872918B2
(en)
|
2012-12-12 |
2018-01-23 |
Mersana Therapeutics, Inc. |
Hydroxyl-polymer-drug-protein conjugates
|
WO2014096551A1
(fr)
|
2012-12-21 |
2014-06-26 |
Glykos Finland Oy |
Conjugués constitués de molécules de charge utile et de lieurs
|
US20150182634A1
(en)
|
2012-12-28 |
2015-07-02 |
Cody P. Coyne |
Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action
|
EP2964245A4
(fr)
|
2013-01-19 |
2016-09-21 |
Univ New York |
Peptides et peptidomimétiques de substitution à liaison hydrogène pour la réactivation du p53
|
WO2014113794A2
(fr)
|
2013-01-19 |
2014-07-24 |
New York University |
Oligooxopipérazines pour la réactivation du p53
|
US20140220112A1
(en)
|
2013-02-01 |
2014-08-07 |
Zoneone Pharma, Inc. |
Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
|
EP2950784B1
(fr)
|
2013-02-01 |
2021-04-07 |
Zoneone Pharma, Inc. |
Chargement à distance de médicaments médiocrement solubles dans l'eau dans des liposomes
|
US9849193B2
(en)
|
2013-02-08 |
2017-12-26 |
University Of Louisville Research Foundation, Inc. |
Nanoparticles for drug delivery
|
US9333211B2
(en)
|
2013-02-22 |
2016-05-10 |
University Of Houston System |
Phosphaplatin mediated modulation of pigment epithelial derived factor and uses thereof
|
US9376437B2
(en)
|
2013-03-13 |
2016-06-28 |
Oncoceutics, Inc |
7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
|
WO2015073072A1
(fr)
|
2013-11-15 |
2015-05-21 |
Oncoceutics, Inc. |
7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
|
NZ711948A
(en)
|
2013-03-13 |
2020-02-28 |
Oncoceutics Inc |
Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
|
US20160022829A1
(en)
|
2013-03-14 |
2016-01-28 |
Mersana Therapeutics, Inc. |
Tubulysin compounds and conjugates thereof
|
CN105377252A
(zh)
|
2013-03-14 |
2016-03-02 |
佛罗里达大学研究基金会 |
利用天然化合物和/或饮食调控癌症
|
US20140271923A1
(en)
|
2013-03-14 |
2014-09-18 |
Christopher Brian Reid |
Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
|
MY174813A
(en)
|
2013-03-15 |
2020-05-16 |
Zymeworks Inc |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
US9295731B2
(en)
|
2013-04-01 |
2016-03-29 |
Mark Quang Nguyen |
Cleavable drug conjugates, compositions thereof and methods of use
|
US10233219B2
(en)
|
2013-04-12 |
2019-03-19 |
Tufts Medical Center |
Methods and systems for designing and/or characterizing soluble lipidated ligand agents
|
WO2014176284A1
(fr)
|
2013-04-22 |
2014-10-30 |
Avelas Biosciences, Inc. |
Compositions et procédés d'utilisation pour l'administration sélective de médicaments
|
GB2513405A
(en)
|
2013-04-26 |
2014-10-29 |
Adc Biotechnology Ltd |
Method of synthesising ADCs using affinity resins
|
ES2759503T3
(es)
|
2013-05-02 |
2020-05-11 |
Glykos Finland Oy |
Conjugados de una glicoproteína o un glicano con una carga útil tóxica
|
AR096238A1
(es)
|
2013-05-15 |
2015-12-16 |
Alphora Res Inc |
Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
|
GB201309807D0
(en)
|
2013-05-31 |
2013-07-17 |
Pharma Mar Sau |
Antibody drug conjugates
|
US20140363454A1
(en)
|
2013-06-06 |
2014-12-11 |
Igenica Biotherapeutics, Inc. |
Antibody-Drug Conjugates, Compositions and Methods of Use
|
US11229711B2
(en)
|
2013-06-06 |
2022-01-25 |
Magenta Therapeutics, Inc. |
Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
|
US10071169B2
(en)
|
2013-06-20 |
2018-09-11 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
JP6744212B2
(ja)
*
|
2013-06-21 |
2020-08-19 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
ポリペプチドの酵素的結合
|
WO2014206466A1
(fr)
|
2013-06-26 |
2014-12-31 |
Afg Technologies S.À.R.L |
Criblage, diagnostic, pronostic et traitement du cancer des ovaires
|
AU2014286880B2
(en)
|
2013-07-03 |
2017-12-14 |
Sandoz Ag |
Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing -SO2-(p-TOLYL) groups
|
WO2015017729A1
(fr)
|
2013-07-31 |
2015-02-05 |
Virginia Tech Intellectual Properties, Inc. |
Procédés de diélectrophorèse pour déterminer une propriété d'une pluralité de cellules cancéreuses
|
US20160166637A1
(en)
|
2013-08-02 |
2016-06-16 |
Virginia Tech Intellectual Properties, Inc. |
Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
|
EP3892294A1
(fr)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Procédés et compositions de conjugaison d'anticorps spécifique à un site
|
US20150093399A1
(en)
|
2013-08-28 |
2015-04-02 |
Bioasis Technologies, Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
EP3338793A1
(fr)
|
2013-08-28 |
2018-06-27 |
AbbVie Stemcentrx LLC |
Nouveaux modulateurs sez6 et procédés d'utilisation
|
JP2016537010A
(ja)
|
2013-09-09 |
2016-12-01 |
ブリティッシュ コロンビア キャンサー エージェンシー ブランチ |
予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット
|
WO2015038426A1
(fr)
|
2013-09-13 |
2015-03-19 |
Asana Biosciences, Llc |
Lieurs auto-immolables contenant des dérivés d'acide mandélique, conjugués médicament-ligand pour thérapies ciblées, et leurs utilisations
|
US20150093331A1
(en)
|
2013-10-01 |
2015-04-02 |
OncoLock Co., Ltd. |
Biomarkers for breast cancer
|
US9878049B2
(en)
|
2013-10-09 |
2018-01-30 |
The University Of Akron |
High drug loading system to co-deliver anticancer drugs and nucleic acids for cancer therapy
|
AU2014331714B2
(en)
|
2013-10-11 |
2019-05-02 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
CN105813655B
(zh)
|
2013-10-11 |
2022-03-15 |
阿萨纳生物科技有限责任公司 |
蛋白-聚合物-药物缀合物
|
MX2016003744A
(es)
|
2013-10-11 |
2016-08-11 |
Us Health |
Anticuerpos tem8 y su uso.
|
US9617521B2
(en)
|
2013-10-21 |
2017-04-11 |
Hemoshear, Llc |
In vitro model for a tumor microenvironment
|
CN114716453A
(zh)
|
2013-11-04 |
2022-07-08 |
卫材R&D管理有限公司 |
软海绵素b的类似物合成中有用的大环化反应和中间体
|
WO2015069266A1
(fr)
|
2013-11-07 |
2015-05-14 |
Flynn Daniel L |
Méthodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer
|
US9457019B2
(en)
|
2013-11-07 |
2016-10-04 |
Deciphera Pharmaceuticals, Llc |
Methods for inhibiting tie-2 kinase useful in the treatment of cancer
|
CN106163524B
(zh)
|
2013-11-15 |
2019-11-08 |
昂克希尔迪克斯有限公司 |
7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法
|
WO2015081282A1
(fr)
|
2013-11-27 |
2015-06-04 |
Redwood Bioscience, Inc. |
Composés hydrazinyl-pyrrolo et procédés de production d'un conjugué
|
EP3077399B1
(fr)
|
2013-12-06 |
2019-02-20 |
Eisai R&D Management Co., Ltd. |
Procédés utiles pour la synthèse d'analogues d'halichondrine b
|
WO2015095784A1
(fr)
|
2013-12-19 |
2015-06-25 |
Luminus Biosciences, Inc. |
Formulation de nanoparticules solides d'inhibiteurs des microtubules à mûrissement d'ostwald réduit pour une administration par voie orale
|
US20160375234A1
(en)
|
2014-01-10 |
2016-12-29 |
Atossa Genetic Inc. |
Transpapillary methods and compositions for diagnosing and treating breast conditions
|
US10548985B2
(en)
|
2014-01-10 |
2020-02-04 |
Birdie Biopharmaceuticals, Inc. |
Compounds and compositions for treating EGFR expressing tumors
|
WO2015106164A1
(fr)
|
2014-01-10 |
2015-07-16 |
Rgenix, Inc. |
Agonistes du récepteur x du foie et leurs utilisations
|
CN104784699B
(zh)
|
2014-01-20 |
2019-05-03 |
博瑞生物医药(苏州)股份有限公司 |
叶酸受体结合配体-药物偶联物
|
JP5957637B2
(ja)
*
|
2014-02-03 |
2016-07-27 |
国立研究開発法人国立がん研究センター |
抗TissueFactorモノクローナル抗体
|
WO2015114171A1
(fr)
|
2014-02-03 |
2015-08-06 |
Eidgenoessische Technische Hochschule Zurich |
Conjugués de médicaments à petites molécules
|
EP2913064A1
(fr)
|
2014-02-26 |
2015-09-02 |
celares GmbH |
Conjugués de lieurs de médicaments ramifiés pour le couplage à des molécules biologiques de ciblage
|
TW201617326A
(zh)
|
2014-03-06 |
2016-05-16 |
Alphora研發股份有限公司 |
(s)-1-((2r,3r,4s,5s)-5-烯丙-3-甲氧-4-(對甲苯磺醯甲基)四氫呋喃-2-基)-3-氨基丙-2-醇之結晶衍生物
|
CA2941161A1
(fr)
|
2014-03-13 |
2015-09-17 |
F.Hoffmann-La Roche Ag |
Methodes et compositions pour moduler des mutants du recepteur des oestrogenes
|
US9260478B2
(en)
*
|
2014-04-04 |
2016-02-16 |
Shanghui Hu |
Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
|
EP3967303A1
(fr)
|
2014-04-08 |
2022-03-16 |
The Methodist Hospital |
Compositions inhibitrices d'inos et leur utilisation comme agents thérapeutiques de cancer du sein
|
WO2015160833A1
(fr)
|
2014-04-14 |
2015-10-22 |
Endocyte, Inc. |
Conjugués pour l'administration de médicaments destinés au traitement de cancers résistants et pour une utilisation en thérapie combinée
|
WO2015161247A1
(fr)
*
|
2014-04-17 |
2015-10-22 |
Igenica Biotherapeutics, Inc. |
Anticorps anti-c16orf54 humanisés et leurs méthodes d'utilisation
|
WO2015195925A1
(fr)
*
|
2014-06-18 |
2015-12-23 |
Mersana Therapeutics, Inc. |
Conjugués médicament-protéine-polymère et leurs procédés d'utilisation
|
TWI695011B
(zh)
*
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
EP3069734A1
(fr)
*
|
2015-03-17 |
2016-09-21 |
Exiris S.r.l. |
Conjugués anticorps-médicament à base de cryptophycine avec de nouveaux lieurs auto-immolateurs
|
US10975112B2
(en)
*
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
WO2015151079A2
(fr)
|
2015-06-20 |
2015-10-08 |
Hangzhou Dac Biotech Co, Ltd |
Analogues d'auristatine et leur conjugués avec des molécules de liaison cellulaire
|